Short Squeeze Stocks: The Usual Suspects, & One Newcomer

Short-interest screen using the most recent reporting period (3/1) flags biotech and software as the most heavily shorted sectors and identifies names where added shorts may now be at substantial losses. The analyst backtested the past year of short-interest reports and assumed shorts were added at the two-week prior average price to estimate potential short returns. Notable tickers called out: Applied Digital (APLD), Nebius Group NV (NBIS) and Nektar Therapeutics (NKTR). These are assumption-driven signals that could trigger isolated short-covering rallies in individual names but are unlikely to move broader markets.

Analysis

Think in terms of positioning amplification, not just binary outcomes. When a stock has concentrated derivative and borrow demand, a 10–20% move can cascade into 2–3x price moves over days as dealers delta-hedge and borrowers scramble for cover; that creates ripe short-term asymmetric payoffs for directional entry but also large tail risk if liquidity evaporates. For APLD, the most relevant second-order levers are locality-specific power contracts and counterparty covenant triggers — squeezes that push spot rent or power costs can materially change free cash flow within a quarter.

For NBIS, the structural story is hardware cadence and hyperscaler demand: revenue lumpyness around GPU shipments and OEM supply contracts means near-term upside can be front-loaded into one quarter while downside reverberates over multiple quarters via renewal dynamics; a one-time large order can double margin visibility. For NKTR, binary clinical/regulatory outcomes dominate valuation — but the market often over-penalizes pre-readout commercial optionality (partner co-development, milestone receipts), creating multi-month opportunities for defined-risk option structures.

Time horizon segmentation matters: expect gamma and positioning squeezes over days–weeks, earnings/data-driven re-ratings over weeks–months, and fundamental resets over quarters–years. Key reversers are sudden increases in borrow cost/liquidity withdrawal, negative trial/data surprises, or a large, opportunistic share issuance. Position sizing should be calibrated to event windows and liquidity: treat these as tactical, not core, allocations and use cost-limited instruments where possible.

Key Decisions for Investors

• APLD — Tactical long call spread: buy 3–6 month 1x2 call spread (long nearer-OTM call, short twice the further-OTM call) sized at 1–2% NAV. Target asymmetric 2.5–4x return if stock gaps >30% in 30–90 days; cut premium at -50% or roll down on muted moves. Rationale: captures fast gamma without open-ended equity downside.
• NBIS — Pair trade: small long equity position (0.5–1% NAV) funded by shorting a larger AI-infra ETF or correlated large-cap (~1% NAV) to neutralize market beta. Add 6–12 month call protection on the long leg if funding is cheap. Aim: capture idiosyncratic upside from order wins while limiting sector drawdowns; close within earnings/order-announcement window (1–3 months).
• NKTR — Defined-risk clinical play: buy 6–12 month call spreads sized at 0.5–1% NAV ahead of the next clinical milestone; alternatively sell one-to-two-month OTM puts for credit if willing to own at a discount. Expect binary payoffs; set hard stop to preserve premium (loss limit 50%) and trim on any >40% single-session run.
• Portfolio risk control — Limit aggregate exposure to these event/timing trades to 5% NAV, with no single-name equity >2% and options positions sized so max premium loss per name <1% NAV. Monitor borrow rates and dealer spreads daily; exit or hedge immediately if borrow spikes >200–300bps intraday or if option skew collapses.